Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
520 participants
INTERVENTIONAL
2022-07-27
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
NCT05131997
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
NCT05202405
Lipid Efficacy Study (0524B-022)(COMPLETED)
NCT00269217
A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A
NCT07152873
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
NCT06747936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Comparator : Test group
AD-218
AD-218
PO, Once daily(QD), 12weeks
Active Comparator : Control group
AD-218A
AD-218A
PO, Once daily(QD), 12weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-218
PO, Once daily(QD), 12weeks
AD-218A
PO, Once daily(QD), 12weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sign on ICF prior to study participation
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyu Chang Won, M.D., Ph.D
Role: PRINCIPAL_INVESTIGATOR
Yeungnam University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yeongnam University Hospital
Daegu, Nam-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Kyu Chang Won, M.D., Ph.D
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kyu Chang Won, M.D., Ph.D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-218P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.